With 0.77 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.21 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $7.19 whereas the lowest price it dropped to was $6.62. The 52-week range on LFCR shows that it touched its highest point at $7.99 and its lowest point at $3.68 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 0.81.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LFCR was up-trending over the past week, with a rise of 6.67%, but this was up by 20.55% over a month. Three-month performance dropped to -6.01% while six-month performance rose 49.15%. The stock gained 36.17% in the past year, while it has lost -5.25% so far this year. A look at the trailing 12-month EPS for LFCR yields -0.58 with Next year EPS estimates of -0.64. For the next quarter, that number is -0.15. This implies an EPS growth rate of -392.19% for this year and 31.55% for next year.
Float and Shares Shorts:
At present, 36.98 million LFCR shares are outstanding with a float of 32.86 million shares on hand for trading. On 2025-03-14, short shares totaled 2.46 million, which was 663.00005 higher than short shares on 1739491200. In addition to Mr. Paul Josephs as the firm’s President, CEO & Director, Mr. James G. Hall serves as its Advisor.
Institutional Ownership:
Through their ownership of 0.73598 of LFCR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-11-24, LFCR reported revenue of $32564000.0 and operating income of -$1959000.0. The EBITDA in the recently reported quarter was -$219000.0 and diluted EPS was -$0.25.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With LFCR analysts setting a high price target of 10.0 and a low target of 10.0, the average target price over the next 12 months is 10.0. Based on these targets, LFCR could surge 42.05% to reach the target high and rise by 42.05% to reach the target low. Reaching the average price target will result in a growth of 42.05% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.41575 being high and $0.40425 being low. For LFCR, this leads to a yearly average estimate of $0.41. Based on analyst estimates, the high estimate for the next quarter is $0.0 and the low estimate is -$0.07. The average estimate for the next quarter is thus -$0.04.
